ERBB2 and breast carcinoma: In particular, the improved outcomes reported for trastuzumab, a monoclonal antibody against the human epidermal growth factor receptor 2 (HER2) in the treatment of HER2-positive breast cancer have highlighted the importance of molecularly targeted therapy development in breast cancers [3].